- Our Story
- Mission & Values
- Corporate Fact Sheet
- Social Responsibility
- Ethical Research & Development
- Conscientious Collaboration
Amy A. Wendell
Senior Vice President
Strategy & Business Development
Amy A. Wendell is Senior Vice President of Strategy and Business Development of Covidien plc, a position she has held since December 2006.
In this position, Ms. Wendell manages all business development, including acquisitions, divestitures and licensing/distribution, and leads the Company’s strategy and portfolio management initiatives. She played a key role in managing the acquisitions of ev3, Sherwood Davis & Geck, U.S. Surgical, Mallinckrodt and more than 60 other transactions for Covidien (formerly known as Tyco Healthcare). In addition, Ms. Wendell is involved with organic growth initiatives, specifically focusing on new product development. She and a team of colleagues developed and implemented a new stage-gate product development process that has been established across the organization.
Ms. Wendell joined the Kendall Healthcare Products Company, the foundation of the Covidien business, in 1986 as a Development Engineer. For the next five years, she held various positions, including Research Engineer and Section Manager, before becoming a Product Manager in Kendall’s vascular therapy division in 1992. She was promoted to Director of Business Development for Kendall in 1995, and a year later her responsibilities were broadened to include international business development. In 1998, she was named Vice President of Covidien Business Development.
Ms. Wendell is a graduate of Lawrence Institute of Technology, which is now the Lawrence Technological University (Michigan), where she received a Bachelor of Science degree in Mechanical Engineering. She also holds a Master of Science degree in Biomedical Engineering from the University of Illinois.